DRUG UTILIZATION PATTERN OF CANCER CHEMOTHERAPEUTIC DRUGS IN HOSPITALIZED PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL IN GOA: A CROSS-SECTIONAL OBSERVATIONAL STUDY

Chemotherapy remains a cornerstone of cancer management but is often accompanied by significant toxicity and economic burden. Drug Utilization Studies (DUS) are essential for evaluating prescribing practices and ensuring rational, cost-effective therapy. This retrospective cross-sectional study analyzed the drug utilization patterns of 400 oncology patients at Goa Medical College between February and March 2024. Data was assessed using WHO prescribing indicators and descriptive statistics. Of the patients, 70% were female, and breast cancer being the most common diagnosis (49.5%). Paclitaxel (38%), trastuzumab (35%), and cyclophosphamide (28%) were the most frequently prescribed chemotherapeutic agents. The supportive drugs included palonosetron (82%), dexamethasone (70%), and ranitidine (63%). Advanced agents such as Zoledronic Acid and Leuprolide were used for bone metastases and hormone-sensitive cancers. High-cost biologics, such as Bevacizumab and Rituximab, were provided under the MJPJAY scheme, ensuring universal access. Injectable formulations accounted for 87% of prescriptions, 97.3% of which were prescribed by generic name, and 100% were listed in the WHO Essential Medicines List. Antibiotic use was low (3%), indicating strong antimicrobial stewardship in the unit. The findings reflect high adherence to rational prescribing practices and demonstrate the effectiveness of a government-funded model for delivering equitable cancer care.